Evidence map›Paper›PMID 39125006›Full record

ArticleMolecules (Basel, Switzerland)2024

UPLC-MS/MS-Based Target Screening of 90 Phosphodiesterase Type 5 Inhibitors in 5 Dietary Supplements.

Shaoming Jin, Yaonan Wang, Xiao Ning, Tongtong Liu, Ruiqiang Liang, Xinrong Pei, Jin Cao

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shaoming JinNational Institute for Food and Drug Control, Beijing 100050, China.ORCID 0000-0001-6910-2361
Yaonan WangSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.ORCID 0000-0003-2159-2730
Xiao NingNational Institute for Food and Drug Control, Beijing 100050, China.
Tongtong LiuNational Institute for Food and Drug Control, Beijing 100050, China.
Ruiqiang LiangNational Institute for Food and Drug Control, Beijing 100050, China.
Xinrong PeiNational Institute for Food and Drug Control, Beijing 100050, China.ORCID 0000-0002-9098-9857
Jin CaoNational Institute for Food and Drug Control, Beijing 100050, China.

Funding

National Key Research and Development Program of China 2021YFC2401100
6 · The paper itself

Abstract

The aim of individuals consuming health supplements is to attain a robust state through nutritional regulation. However, some unscrupulous manufacturers, motivated by profit, fraudulently incorporate drugs or unauthorized components with therapeutic effects into the product for instant product performance enhancement. The long-term use of these products may inadvertently inflict harm on human health and fail to promote nutritive healthcare. The illegal inclusion of these substances is prevalent in kidney-tonifying and sexuality-enhancing products. Developing effective analytical methods to identify these products and screen for illegal added ingredients can effectively prevent such products from reaching and remaining on the market. A target screening method for the detection and quantification of 90 phosphodiesterase type 5 inhibitors (PDE-5is) in 5 kinds of health products was developed and validated. The type of dietary supplements varied from tablets, capsules, and protein powder to wine and beverages. Sample preparation was completed with a one-step liquid phase extraction. The screening process of 90 PDE-5is was done efficiently within 25 min by ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) using the dynamic multiple reaction monitoring (dMRM) technique. The LODs of 90 PDE-5is were detected at levels ranging from 25 to 85 ng/g or ng/mL. This novel targeting methodology was effective and can be applied to routine market supervision. Among 286 batches of samples, 8 batches were found to be positive. Three kinds of PDE-5is were first detected in healthy products. The screening method demonstrated herein will be a promising and powerful tool for rapid screening of PDE-5is.

Indexed as

Dietary SupplementsLiquid Chromatography-Mass SpectrometryPhosphodiesterase 5 InhibitorsChromatography, High Pressure LiquidHumansTandem Mass SpectrometryPhosphodiesterase 5 Inhibitorsillegal additionphosphodiesterase type 5 inhibitorstarget screeningUPLC-MS/MS

Identifiers

PMID39125006
PMCPMC11313696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.